Abstract:Objective: Inhibition of the renin-angiotensin system (RAS) with ACE inhibitors (ACEi) or angiotensin receptor blockers (ARB) is associated with concentric thickening of renal arteries and arterioles and parenchymal disease. Here we evaluated to what degree this also occurs during RAS inhibition with siRNA targeting hepatic angiotensinogen (AGT). Methods: Male hypertensive heterozygous transgenic rats overexpressing mouse renin (TGR(mRen2)27 rats), made diabetic with streptozotocin, were treated with the ARB valsartan (4 mg/kg/day), the ACEi captopril (6 mg/kg/day), AGT siRNA (30 mg/kg every 2 weeks), AGT siRNA + valsartan, or captopril+valsartan for 3 weeks, starting at 15 weeks after induction of diabetes. After 3 weeks of treatment, kidneys were removed, and immunocytochemistry was performed on Bouin's fixed kidney sections using antibodies against renin or α-smooth muscle actin. Juxtaglomerular index and wall thickness were assessed using tiling pictures of both renin and α-smooth muscle actin sections from the slides. Tubular degeneration was scored by summing up scores for tubular atrophy, interstitial fibrosis, and tubulointerstitial inflammation. Concentric vascular hypertrophy was assessed in a blinded manner. Results: All treatments increased juxtaglomerular index, and the largest increases were observed in dual treatment groups, consistent with the highest degree of RAS blockade in these groups. Tubular scores increased after induction of diabetes, and the highest scores were seen in dual treatment groups, significance versus vehicle being reached in the valsartan+captopril group only (P<0.05). Afferent arteriole wall thickness increased in all treatment groups, and the greatest increases were observed during dual treatment. Finally, concentric vascular hypertrophy was observed in 1 of 7 diabetic Ren2 rats; this percentage increased during RAS blocker treatment of these rats, numerically reaching the highest values during dual treatment. Conclusions: Our data suggest that, in the hypertensive diabetic rat model, high levels of RAS blockade, irrespective of the type of blockade, may result in an increase in afferent arteriole thickness and concentric vascular hypertrophy. AGT siRNA in combination with RAS inhibitors should be further explored in clinical studies.

Angiotensinogen Inhibition Reduces Atherosclerosis And Body Weight Gain Induced By High-Carbohydrate Diet

Angiotensinogen in Hepatocytes Contributes to Western Diet-Induced Liver Steatosis

Abstract 352: Adeno-Associated Virus-mediated Restoration of Angiotensinogen Function in Mice with Hepatocyte-specific Deficiency

Abstract 5457: Angiotensinogen Hypomorphic Mice Have Markedly Reduced Hypercholesterolemia-induced Atherosclerosis

Effects of Human Angiotensinogen and Human Renin in Proximal Tubule Cells on Development of Atherosclerosis in Hypercholesterolemic Mice

Abstract 636: Angiotensinogen and Megalin Interaction Contribute to Renal Angiotensin II Production and Hypercholesterolemia-induced Atherosclerosis

Abstract 227: Megalin Regulates Angiotensinogen and Contributes to Atherosclerosis

Angiotensinogen and Megalin Interactions Contribute to Atherosclerosis-Brief Report

Hepatocyte-Specific Angiotensinogen Deficiency Markedly Reduces Hypercholesterolemia-Induced Atherosclerosis And Diet-Induced Obesity In Mice

Suppression of Diacylglycerol Acyltransferase-2 (DGAT2), but Not DGAT1, with Antisense Oligonucleotides Reverses Diet-Induced Hepatic Steatosis and Insulin Resistance.

Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice

Over-expression of Angiotensin II Type 2 Receptor (agtr2) Reduces Atherogenesis and Modulates LOX-1, Endothelial Nitric Oxide Synthase and Heme-Oxygenase-1 Expression

Apigetrin attenuates high fat diet-induced intestinal inflammation and nonalcoholic fatty liver disease (NAFLD) process

O52 KIDNEY ARTERIOLAR RESPONSES TO LIVER-TARGETED SMALL INTERFERENCE RNA (SIRNA) TARGETING ANGIOTENSINOGEN IN DIABETIC RATS: COMPARISON WITH OTHER RENIN-ANGIOTENSIN SYSTEM BLOCKERS

WITHDRAWN: Molecular Mechanisms of Irbesartan Suppressing Atherosclerosis in High Cholesterol-Diet Apolipoprotein E Knock-out Mice

Angptl8 antisense oligonucleotide improves adipose lipid metabolism and prevents diet-induced NAFLD and hepatic insulin resistance in rodents

Effect of GPE-AGT Nanoparticle Shrna Transfection System Mediated RNAi on Early Atherosclerotic Lesion.

Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model

Reduced intake of carbohydrate prevents the development of obesity and impaired glucose metabolism in ghrelin O-acyltransferase knockout mice

Abrogating monoacylglycerol acyltransferase activity in liver improves glucose tolerance and hepatic insulin signaling in obese mice.

Development of obesity can be prevented in rats by chronic icv infusions of AngII but less by Ang(1-7)